



RNS Number : 8200E  
Integrated Diagnostics Holdings PLC  
09 July 2021

**Integrated Diagnostics Holdings plc  
(the "Company")**

**Final dividend clarification**

**9 July 2021**

**(Cairo and London)** - In reference to resolution 10 approved by shareholders at the Annual General Meeting (AGM) of the Company held on 30 June 2021, the Company notes that the final dividend to be distributed on 29 July 2021 amounts to US\$ 29.1 million in aggregate for the year ended 31 December 2020 (as previously stated in the FY2020 and 1Q2021 results announcements issued on 19 May 2021 and 2 June 2021, respectively). This equates to a dividend of US\$ 0.0485 per share (due to an administrative oversight the figure was rounded to three rather than four decimal places to US\$ 0.049 in the AGM Circular and Summary of Proxy Voting documents issued on 7 June 2021 and 30 June 2021, respectively), and is 4% higher than the US\$ 28.0 million in aggregate distributed in the previous financial year.

-Ends-

**About Integrated Diagnostics Holdings (IDH)**

IDH is a leading consumer healthcare company in the Middle East and Africa with operations in Egypt, Jordan, Sudan and Nigeria. The Group's core brands include Al Borg, Al Borg Scan and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and Echo-Lab (Nigeria). A long track record for quality and safety has earned the Company a trusted reputation, as well as internationally recognised accreditations for its portfolio of over 2,000 diagnostics tests. From its base of 483 branches as of 31 March 2021, IDH will continue to add laboratories through a Hub, Spoke and Spike business model that provides a scalable platform for efficient expansion. Beyond organic growth, the Group's expansion plans include acquisitions in new Middle Eastern, African, and Asian markets where its model is well-suited to capitalise on similar healthcare and consumer trends and capture a significant share of fragmented markets. IDH has been a Jersey-registered entity with a Standard Listing on the Main Market of the London Stock Exchange (ticker: IDHC) since May 2015 with a secondary listing on the EGX since May 2021 (ticker: IDHC.CA). Learn more at [idhcorp.com](http://idhcorp.com).

The person responsible for arranging the release of this announcement is Nancy Fahmy, Investor Relations Director at IDH.

**Contact**

**Nancy Fahmy**

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)12 2255 7445 | [nancy.fahmy@idhcorp.com](mailto:nancy.fahmy@idhcorp.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

DIVUPUCGMUPGGAB